Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 and older, male and female~2. Patients must consent in writing to participate in the study by signing and dating an informed consent document~3. Diagnosis of osteoarthritis by ACR osteoarthritis of the knee~4. Diagnosis of osteoarthritis by radiographic criteria of Kellgren and Lawrence grade 2-4~5. More than Grade 4 (0\~10 point numeric scale) pain at least for 12 weeks~6. Diagnosis of osteoarthritis of class Ⅰ\~Ⅲ by ACR(American College of Rheumatology Criteria) Global functional criteria~7. Patient who agree with contraception~Exclusion Criteria:~1. Preparing for Pregnancy or Pregnant women or lactating mothers.~2. Patients with Body Mass Index (BMI) \> 35.~3. Patients with other disease including~   : Septic arthritis, Rheumatoid or Inflammatory joint disease, Crystalline disease (gout or pseudogout), Paget disease, Articular fractures, Ochronosis, Acromegaly, Hemochromatosis, Wilson's disease, Osteochondromatosis, Hereditary disorder~4. Patients with serious condition internal medicine disease~5. Patients with positive human immunodeficiency (HIV), hepatitis B (HBV), hepatitis C (HCV), syphilis at screening indicative of current of pass infection.~6. Patient with behavioral disorders, cognitive disorders and chronic mental symptoms~7. Patient with significant neurologic or psychiatric disorders~8. Patients who alcohol, drug abuse history~9. Patients who had participated in other clinical trials within 12 weeks prior to this study.~10. Patients who received any drug by intra-articular injection for treatment within 2 months prior to this enrollment.~11. Patients who experienced as the knee joint cartilage and stem cell therapy~12. Patients who the principal investigator considers inappropriate for the clinical trial due to any other reasons than those listed above~13. Patients who penicillin hypersensitivity reactions -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Jointstem (Type: EXPERIMENTAL): Autologous Adipose Tissue derived MSCs
- Saline solution (Type: PLACEBO_COMPARATOR): Sodium chloride

Based on this trial design, predict the completion outcome and termination type (if applicable).